Immorta Bio

Executive Summary

Immorta Bio is a private longevity biotechnology company headquartered in San Diego, California, founded in 2021. The company is developing novel therapeutics that target senescent cells and leverage stem cells to reverse biological aging and treat age-related diseases. By addressing the root causes of aging, Immorta Bio aims to extend healthy human lifespan. The company operates in the cell and gene therapy space, focusing on two complementary approaches: clearance of senescent cells and stem cell-based regeneration. While still in early stages with no disclosed funding rounds or valuation, Immorta Bio represents a promising player in the rapidly growing longevity sector. The company's science aligns with emerging trends in geroscience, but it faces significant development and regulatory hurdles typical of early-stage biotech firms. The success of the platform will depend on preclinical proof-of-concept, ability to attract capital, and eventual clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data for lead asset60% success
• Q4 2026Series A financing round50% success
• TBDIND filing for first-in-human study30% success